Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diagnostics
Company acquires rights from McGill University to breast cancer markers
January 13th, 2005
DiagnoCure, Inc., (CUR), a developer and provider of immunoassay and molecular diagnostics for early detection of cancer, has acquired a worldwide exclusive license from McGill University to the CDP/Cux protein technology for the detection of breast cancer. Under the terms of the agreement, DiagnoCure's rights to this technology also extend to the detection of any other cancer. During the past 3 years, the research team of Dr. Alain Nepveu, professor in the departments of medicine, biochemistry, and oncology at McGill University in collaboration with the University of Manitoba and the University of California at San Francisco (California), has shown...
Source: Women's Health Weekly (2005-01-13)
|
